Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles SEC filings for AdaptHealth Corp. (NASDAQ: AHCO), a company that describes itself as a national provider of patient-centered, healthcare-at-home solutions. Its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker AHCO, as disclosed in its current reports.
AdaptHealth’s recent regulatory filings include multiple current reports on Form 8-K. These filings furnish press releases announcing quarterly financial results for periods ended June 30 and September 30, along with updates to financial guidance and information on the closing of dispositions of certain assets in its Wellness at Home segment. The 8-Ks also cover a new capitated partnership with a large integrated delivery network and provide details on the company’s annual meeting of stockholders, including votes on director elections, auditor ratification, and advisory approval of executive compensation.
Through these filings, readers can review how AdaptHealth reports net revenue, net income, and cash flow, and how it discusses non-GAAP measures such as EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, free cash flow, and organic revenue. The company explains in its press releases, furnished as exhibits to the 8-Ks, how these metrics are used in its operational and financial decision-making and how they relate to its credit agreements.
Stock Titan’s SEC filings page presents these AdaptHealth documents with AI-powered summaries that highlight key items, such as earnings announcements, guidance changes, asset sales, and partnership disclosures. Users can quickly locate 8-Ks and related exhibits, and track how the company communicates material events, capital structure developments, and governance matters through the EDGAR system.
AdaptHealth Corp. furnished an update on its recent performance by issuing a press release with financial results for the quarter ended September 30, 2025. The company released these results on November 4, 2025 and attached the full press release as an exhibit to this report.
The disclosure is provided under the results of operations and financial condition section and is treated as “furnished” rather than “filed,” which limits certain legal liabilities. The press release is identified as Exhibit 99.1, with an additional exhibit covering the interactive data for the cover page.
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. (AHCO) – Form 4 insider activity
Director Theodore B. Lundberg reported two acquisitions of AdaptHealth common stock on 06/26/2025:
- 21,346 shares acquired
- 7,864 shares acquired
Both transactions are recorded at $0, indicating they were equity grants or similar non-cash awards rather than open-market purchases. Following the transactions, Lundberg’s direct beneficial ownership rose to 859,756 shares. No dispositions, derivative securities, or 10b5-1 plan designations were disclosed, and the filing lists a Power of Attorney (Exhibit 24) supporting the submission.
The Form 4 contains no additional financial metrics or narrative commentary.
SEC Form 4 filed on 06/30/2025 shows AdaptHealth Corp. (AHCO) director Gregory Belinfanti acquired a total of 28,086 common shares on 06/26/2025 through two transactions recorded at $0.00 per share, indicating stock awards rather than open-market purchases. His direct holdings rose from an estimated 45,408 shares to 73,494 shares after the grants. No derivative securities were reported. While the amount is modest relative to AHCO’s float, the additional ownership slightly tightens insider–shareholder alignment and is typically viewed as a mildly positive governance signal.